Cingulate Announces Detailed Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD
11 sept. 2023 06h00 HE
|
Cingulate Inc.
CTx-1301 Demonstrated Clinically Meaningful Improvements in Permanent Product Measure of Performance (PERMP) and Clinical Global Impression Scale (CGI-S) Scores, with Investigators Observing Trend...
Werth Family Investment Associates Converts $5.8 Million of Debt into Cingulate Equity at a Premium
08 sept. 2023 16h31 HE
|
Cingulate Inc.
KANSAS CITY, Kan., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING) (Cingulate), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery...
SourceOne Global Partners celebrates 20-year anniversary, reflecting on pioneering a best-in-class high bioavailability technology platform
07 sept. 2023 11h39 HE
|
SourceOne Global Partners
CHICAGO, Sept. 07, 2023 (GLOBE NEWSWIRE) -- SourceOne Global Partners is proud to announce the launch of new, science-backed product solutions as it celebrates twenty years as a leading supplier to...
Cingulate Announces Presentation of Full Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD at Psych Congress 2023
05 sept. 2023 08h00 HE
|
Cingulate Inc.
KANSAS CITY, Kan., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
Global Drug Device Combination Products Market 2023-2028: Boston Scientific Corp and Becton, Dickinson and Company: Innovating Drug Device Combination Solutions
05 sept. 2023 06h28 HE
|
Research and Markets
Dublin, Sept. 05, 2023 (GLOBE NEWSWIRE) -- The "Drug Device Combination Products Market Size & Share Analysis - Growth Trends & Forecasts (2023 - 2028)" report has been added to ...
RNAi Drug Delivery Technologies and Global Market Analysis Report 2023: Historic Market Revenue from 2020 to 2022, Estimates for 2023, and CAGR Projections through to 2028
29 août 2023 07h08 HE
|
Research and Markets
Dublin, Aug. 29, 2023 (GLOBE NEWSWIRE) -- The "RNAi Drug Delivery: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering. The global RNAi drug delivery...
Key Players F. Hoffmann-La Roche, 3M, Pfizer, and More Fuel Global Drug Delivery Devices Market Reaching $115.09 Billion by 2027
16 août 2023 04h43 HE
|
Research and Markets
Dublin, Aug. 16, 2023 (GLOBE NEWSWIRE) -- The "Drug Delivery Devices Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering. This report provides strategists,...
Cingulate Inc. Reports Second Quarter 2023 Financial Results and Provides Clinical and Business Update
14 août 2023 16h15 HE
|
Cingulate Inc.
Werth Family Investment Associates Provides Additional Capital InvestmentPhase 3 Adult Efficacy and Safety Trial of CTx-1301 Data ReleasedCTx-1301 Phase 3 Pediatric and Adolescent Studies Underway ...
Cingulate Announces Positive Top-Line Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD
11 juil. 2023 08h00 HE
|
Cingulate Inc.
KANSAS CITY, Kan., July 11, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
Cingulate Successfully Manufactures Clinical Supply – Initiation of Pediatric Phase 3 Studies to Commence in July and August
29 juin 2023 08h00 HE
|
Cingulate Inc.
KANSAS CITY, Kan., June 29, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...